Predictions of the onset of acute myocardial infarction (AMI) in high risk individuals are of great clinical importance. Among various risk factors, elevated levels of oxidized low density lipoprotein (ox-LDL) in plasma have been shown to reflect unstable coronary plaques. Coronary calcification is a common finding in the elderly, however, its clinical implications as a risk factor for plaque rupture are controversial. This study was designed to investigate the clinical implications of plasma ox-LDL levels and coronary calcification detected by electron-beam computed tomography (EBCT), by comparing patients with AMI with those with stable angina pectoris (SAP). Methods: We measured plasma ox-LDL levels in AMI (n 34) and SAP (n 49) patients. In addition, a coronary calcium score was quantified with the Agatston system. The total coronary calcium score (TCS) was defined as the sum of the scores for each lesion. Results: TCS and total calcium area were significantly smaller in patients with AMI than in those with SAP. On the other hand, plasma ox-LDL levels were significantly higher in AMI patients than in SAP patients (p 0.0005). Conclusion: These results suggest that a combined assessment of coronary calcium and plasma ox-LDL levels may be useful for screening patients with unstable coronary plaques. 
AMI patients were mostly characterized by spotty calcification, associated with fibrofatty plaques and expansive remodeling 2, 3) . Electron-beam computed tomography (EBCT) is extremely sensitive for the detection and quantification of the extent of coronary artery calcification, and some studies have shown that EBCTdetected coronary calcification is a powerful predictor of future coronary events 4, 5) . Raggi et al. also reported that coronary calcification identified by EBCT is highly prevalent in patients who have had an AMI 6) . Imaging of coronary calcium by EBCT is unable to identify a localized unstable plaque, but it can potentially identify an "unstable patient".
Increasing evidence indicates that activation of the inflammatory response in coronary atherosclerotic lesions relates to a rapidly progressive destabilization of plaques 7) . Previous in vitro studies have shown that oxidized low density lipoprotein (ox-LDL) is a key factor in the pathogenesis of these inflammatory processes 8) . Recently, the detection of ox-LDL in circulating plasma has been reported [9] [10] [11] [12] [13] [14] [15] [16] [17] . We developed a new method to determine the levels of ox-LDL in human circulating plasma, using an anti-ox-LDL monoclonal antibody, DLH3 11) . DLH3 is specific for ox-LDL, because it recognizes oxidized phosphatidylcholine (ox-PC) molecules and does not react with either native, acetylated, malondialdehyde-treated, or glycated LDL 18) . With this sensitive method, we demonstrated a significant association between plasma ox-LDL levels and the severity of coronary syndromes 12, 14) . Recently, we also reported that persistence of an elevated level of plasma ox-LDL after an AMI is a strong independent predictor of stent restenosis at 6-month follow-up 17) . The purpose of this study is to investigate the clinical implications of coronary calcium deposits detected by EBCT and plasma ox-LDL levels in patients with AMI and SAP, and whether a combined assessment of coronary calcium and plasma ox-LDL levels is useful for screening patients with unstable coronary plaques.
Materials and Methods
The study was approved by the hospital ethics committee, and informed consent was obtained from all patients before the study.
Subjects
Two groups of patients were studied. The first group consisted of 40 consecutive patients with AMI who underwent percutaneous coronary intervention (PCI) at Osaka City General Hospital between September 2001 and February 2002 and achieved successful coronary reperfusion within 6 hours after the onset of AMI. Patients with a history of coronary heart disease were excluded in the AMI group. The diagnosis of AMI was based on a history of prolonged ischemic chest pain, characteristic ECG changes, and an elevated creatine kinase level (more than 2 times the normal range) within 6 hours after the onset of pain. Stent implantation was performed in 6 of the 40 patients with PCI (15%) because of coronary dissection after plain old balloon angioplasty (POBA) or a suboptimal result (≥ 30%). Because of potential interference with the calcium score calculations, these 6 patients with stent implantation were excluded, and the remaining 34 patients with POBA alone underwent EBCT scanning and formed the AMI group in the present study. The second group consisted of 49 age and gender-matched patients with SAP, who did not have a history of coronary heart disease. SAP was defined as chest pain typical of cardiac ischemia on exertion. In all patients, the procedure was performed on a native "de novo" atherosclerotic lesion, considered to be the culprit lesion. We excluded patients with concomitant inflammatory diseases or patients undergoing dialysis in this study cohort.
Serum levels of total cholesterol, LDL cholesterol, and high density lipoprotein (HDL) cholesterol, serum C-reactive protein (CRP) levels, and plasma ox-LDL levels were measured in both patient groups. Venous blood samples of all patients were obtained on admission to the hospital. For measuring total cholesterol, LDL cholesterol, and HDL cholesterol levels, blood samples were obtained after an overnight fast. Serum levels of CRP were measured by the latex agglutination photometric immunoassay with an automated immunochemistry analyzer (LXz-6000; Eiken Chemical Co., Tokyo, Japan) with normal values of 0.3 mg/dL. The following data were obtained also: age, gender, the presence of risk factors (cigarette smoking, hypertension, diabetes mellitus, and hypercholesterolemia defined as a cholesterol level 220 mg/dL 19) ), and family history of coronary disease. No patients with AMI or SAP received any vitamin or probucol. The inclusion period was limited because primary stent implantation was commonly performed for patients with AMI.
EBCT Scanning
All 83 patients underwent both coronary angiography and an EBCT assessment. The AMI group underwent EBCT scans within 1 month after the onset of AMI (mean 13 8 days) , and the SAP group underwent EBCT scans before coronary angiography. In all patients, EBCT scans were performed using an Imatron C-100 scanner. Images were obtained with a 100-ms scan time and 3-mm single-slice thickness, with a total of 40 slices starting at the level of the carina and proceeding to the level of the diaphragm. Tomographic imaging was electrocardiographically triggered to 60-80% of the R-R interval. Coronary calcification was defined as a volume of 2 consecutive pixels with a CT number 130 HU within the distribution of a coronary artery. All sections of the EBCT scan were then reviewed by an experienced investigator who was blind to the clinical data. The intraobserver correlation was 0.99. A quantitative coronary calcium score was calculated according to the method described by Agatston et al. 20) . The total coronary calcium score (TCS) was defined as the sum of the scores for each lesion. At the same time, the aortic calcium score (ACS) of the descending aorta was examined using the method employed for the coronary calcium score from the slice of the third lumbar vertebra to the aortic bifurcation.
Measurement of Plasma Ox-LDL Levels
The measurement of circulating ox-LDL was performed using a sandwich ELISA method previously described 11, 12) . The LDL fraction was separated from blood plasma before the ELISA procedure to minimize potential interferences with other plasma constituents, such as ox-VLDL, anti-ox-LDL autoantibodies, and anti-phospholipid antibodies. The LDL fractions were obtained from the samples by sequential ultracentrifugation. Diluted LDL fractions (5 g/well) were added to the microtiter wells that were precoated with 0.5 g of the anti-ox-LDL monoclonal antibody DLH3. After extensive washing, the remaining ox-LDL was detected with a sheep anti-human apolipoprotein B antibody and an alkaline phosphatase-conjugated anti-sheep IgG antibody. In each ELISA plate, various concentrations of standard ox-LDL, which was prepared by incubating LDL with 5 mol/L CuSO4 at 37 for three hours, were run simultaneously to determine a standard curve.
Statistical Analysis
The results are expressed as the mean SD. In cases in which the data were normally distributed, the two groups were compared with an unpaired t test. Otherwise, a Mann-Whitney U test was used. Statistical comparisons between more than 3 groups were performed by one-way analysis of variance and posthoc multiple comparison, using Scheffe's test. Plasma ox-LDL levels and TCS did not distribute normally; therefore, transformed values of ox-LDL and TCS in logarithm were used as variables for statistical analyses.
Categorical variables were compared by use of chisquare test. Multivariate logistic regression analysis was performed to identify independent factors associated with AMI. Values of p 0.05 were considered significant.
Results

Patient Characteristics
Clinical characteristics of all 83 patients are shown in Table 1 . There were no statistically significant differences in age, gender, presence of risk factors, serum levels of total cholesterol, LDL cholesterol, or HDL cholesterol, serum CRP levels, the number of diseased coronary arteries, or medications prior to admission between patients with AMI and SAP.
Extent of Calcification
The extent of coronary calcium in patients with AMI and SAP is shown in Table 2 . A high prevalence of coronary calcium (TCS 0) was observed in both groups (AMI: 97%, SAP: 98%). TCS, total calcium area, and ACS were significantly smaller in patients with AMI than in those with SAP. In all patients, TCS showed a positive correlation with ACS (r 0.525, p 0.0001). The prevalence of no (0), mild (1-99), moderate (100-400), and severe ( 400) TCS in patients with AMI and SAP is shown in Fig.1 . In AMI patients, the frequencies of mild, moderate, and severe TCS were nearly equal. In SAP patients, the frequency of severe TCS was the highest. Fig. 2 shows the plasma ox-LDL levels in patients with AMI (n 34) and SAP (n 49). Plasma ox-LDL levels in patients with AMI were significantly higher than those in patients with SAP (p 0.0005) (AMI: 1.39 1.10, SAP: 0.62 0.44 ng/ 5 g LDL protein, mean SD). Fig. 3 shows the relationship between plasma ox-LDL levels and TCS in 81 patients. Two patients with a TCS of zero (1 with AMI and 1 with SAP) were excluded from this analysis. There was no significant correlation between plasma ox-LDL levels and TCS (r 0.067, p 0.552).
Plasma Levels of Ox-LDL and Coronary Calcium
Factors Associated with AMI
To identify independent factors associated with AMI, a multivariate logistic regression analysis was performed using plasma ox-LDL levels and mild ( 99) TCS. The analysis revealed that plasma ox-LDL levels and mild TCS were independent factors associated with AMI ( Table 3) .
Discussion
Our major finding was that there is a significant difference in coronary calcium burden evaluated by EBCT between patients with AMI and SAP. TCS was significantly smaller in patients with AMI than patients with SAP. Previous data obtained with double helical CT showed that a first AMI most often occurs in mildly calcified or noncalcified culprit arteries, while extensive calcification characterizes the coronary arteries of SAP patients 21) . Shemesh et al. also reported that the same prevalence of coronary calcium was observed in AMI (93%) and SAP (95%) patients, and that TCS and total calcium area were significantly smaller in AMI than in SAP. Our data obtained with EBCT support those findings.
It has been shown that ox-LDL plays a key role in the inflammatory process associated with atherosclerotic disease in human coronary arteries 12, 14) . Our group has developed a highly sensitive method to detect minute amounts of ox-LDL particles in the circulation, using only the LDL fraction from blood plasma and not using whole blood plasma, to minimize potential interferences with other plasma substances such as ox-VLDL, anti-ox-LDL autoantibodies, and anti-phospholipid antibodies 11) . Using this sensitive method, we previously demonstrated that plasma ox-LDL levels in patients with AMI are significantly higher than those in patients with either UAP or SAP or in controls 12, 14) . Tsimikas et al. also reported that temporal increases in plasma ox-LDL levels strongly reflect the presence of acute coronary syndromes 13) . However, Braun et al. recently inves- or SAP (n 49) for determination of plasma ox-LDL levels as described in the Methods.
Solid bar; patients with AMI. Open bar; patients with SAP. n; number of patients analyzed. A Mann-Whitney U test was performed. 16) . Whether these conflicting results are due to differences in ox-LDL-measuring methods or other factors is unknown. The present data, from AMI and SAP patients who underwent EBCT assessments and in whom we measured plasma ox-LDL levels, support earlier studies [12] [13] [14] and further strengthen the rotion of a role for ox-LDL in acute coronary syndromes.
Our multivariate analysis, moreover, demonstrated that plasma ox-LDL levels and mild TCS were independent factors associated with AMI. In the present cohort, the AMI group showed significantly smaller TCS than the SAP group, and the majority of AMI patients revealed the presence of small amounts of calcium deposited in coronary artery trees. On the other hand, plasma ox-LDL levels were significantly higher in these AMI patients than in the SAP patients. The biological relevance of this association is not clear, but it may reflect a greater tendency for coronary plaques with small calcium deposits to cause acute coronary events, which could lead to an increase in the levels of plasma ox-LDL. Previous studies have demonstrated that calcified caps were 4 to 5 times stiffer than cellular caps 22) , and that intimal tears often occurred at the interface between calcified and adjacent noncalcified arterial tissues 23) . Hence, one could hypothesize that small and spotty calcium deposits within an atherosclerotic plaque cause differences in tissue stiffness in the plaque, and the junction between the calcified and non-calcified tissues could act as a destabilizer, potentially leading to plaque rupture or fissuring. Indeed, recent clinical studies using IVUS and multislice CT (MSCT) have shown that coronary plaques with small spotty calcium deposits are more prone to rupture than severely calcified plaques [1] [2] [3] 24) . It is conceivable, therefore, that discrete and spotty calcification, which contributes to differences in tissue tensile strength, together with other destabilizing factors such as endothelial dysfunction, plaque inflammation, and lipid accumulation, plays a role in the genesis of coronary plaque instability and the development of acute coronary events, which could cause high levels of plasma ox-LDL.
What is the clinical relevance of this study ? Quantification of coronary calcium by EBCT may well be one of the best noninvasive methods currently available to estimate the extent of coronary atherosclerotic plaque burden. However, as EBCT imaging is insufficient to define coronary plaque characteristics accurately, the combination of a quantitative measure of coronary calcium for the differentiation of disease severity and any marker of plaque instability, such as plasma ox-LDL levels, will be most useful for identifying patients with unstable coronary plaques. Recently, the introduction of MSCT has allowed not only the quantification of calcium burden, but also the identification of the patterns of calcification and the plaque morphology. Hence, we believe that the findings of the present study provide information to complement future studies using MSCT and are valuable because we included patients with AMI without stenting.
Our study has some limitations. First, quantification of coronary calcium deposition by EBCT is a good noninvasive method to estimate the extent of coronary atherosclerotic plaque burden. However, imaging of coronary calcification by EBCT cannot be used to identify a localized unstable plaque and, therefore, has limited predictive value with respect to potential sites of plaque complications. Second, in the present analysis, the number of AMI patients examined was relatively small, because AMI patients who underwent coronary stenting were excluded owing to inaccuracies in measuring coronary calcification. This may have limited the statistical power. Third, EBCT scans were performed within 1 month after angioplasty therapy for AMI, whereas the EBCT scans of the SAP patients were performed before angioplasty. Fourth, detailed information about the control status of blood pressure or blood glucose before coronary events was not available for all patients. On the other hand, in the present study, we measured plasma ox-LDL levels in all 83 patients, using our ox-LDL-measuring method. As we previously described 11, 12, 17) , our method is highly sensitive and allows the detection of ox-PC particles as part of ox-LDL and minimally modified LDL in blood, although it takes 4 days for each measurement. We consider, therefore, that the quality of the plasma data is sufficiently high to warrant our conclusion. However, our method is time consuming and therefore, it is not suitable for mass screening.
In conclusion, this study demonstrates that the combined assessment of coronary calcium and plasma ox-LDL levels is important for screening patients with unstable coronary plaques.
